Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1630991

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1630991

Lysosomal Acid Lipase Deficiency Treatment Market Size, Share & Trends Analysis Report By Indication (Wolman Disease, Cholesteryl Ester Storage Disease), By Treatment, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Lysosomal Acid Lipase Deficiency Treatment Market Growth & Trends:

The global lysosomal acid lipase deficiency treatment market size is expected to reach USD 433.2 million by 2030, registering a CAGR of 7.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, rising prevalence, and increasing uptake of enzyme replacement therapy are some of the primary factors driving the market.

LAL deficiency (LAL-D) is a rare type of lysosomal storage disorder in which patients are unable to breakdown cholesteryl esters and triglycerides due to a mutation in the LAL gene. As a result, there is an accumulation of lipids in the liver, spleen, and walls of blood vessels. LAL deficiency is a progressive disease with multi-systemic clinical manifestations, significant medical complications, and early mortality due to liver failure, especially among infants.

Until 2015, the global LAL deficiency treatment market witnessed modest growth due to a lack of approved treatments for the disease. Medical care was limited to supportive care, with surgery and lipid-modifying drugs such as statins remained the mainstay for treatment. In 2015, approval of Alexion Pharma's Kanuma (sebelipase alfa) marked the entry of enzyme replacement therapy (ERT) in the LAL-D space. Kanuma is a hydrolytic lysosomal cholesterol ester and triacylglycerol specific enzyme, administered intravenously in patients with LAL deficiency. Currently, Kanuma is the only drug approved for both Wolman disease (WD) and Cholesteryl Ester Storage Disease (CESD) in the key markets.

Based on treatment, supportive care was the leading revenue contributor in the market in 2017. However, the ERT segment is expected to register the fastest growth during the forecast period, supported by continued uptake of Kanuma. Disease prognosis remains poor, as a majority of patients are either undiagnosed or misdiagnosed. Thus, there remains a strong need for extensive research to understand disease biology and develop effective therapeutic options with the goal to overcome resistance and minimize toxicity.

Lysosomal Acid Lipase Deficiency Treatment Market Report Highlights:

  • CESD manifests later in life and is more prevalent among Caucasians and Hispanic populations, affecting approximately 1 in 300,000 individuals.
  • Germany is at the forefront of the Europe market and is driven by high disease prevalence and availability of drugs in the ERT class.
  • Approval of Kanuma in ERT class highlight a fundamental shift in treatment approach to LAL-D deficiency.
  • The ERT segment is estimated to be the fastest-growing during the forecast period, owing to Kanuma's first-mover advantage as the only long-term treatment in untapped LAL-D patient population pool.
  • Statins are anticipated to lose market share due to rising competition from generics within the class and increasing uptake of Alexion's Kanuma.
  • Rising eligible patient population and limited therapeutic intervention for LAL deficiency offer a strong commercial opportunity for players to invest in developing novel treatments in this market.
  • Lack of awareness in disease diagnosis and delayed access to medications due to poor prognosis may restrain the growth of the market.
Show more
Product Code: GVR-2-68038-610-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Treatment
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Acid Lipase Deficiency Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lysosomal Acid Lipase Deficiency Treatment Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Wolman Disease (WD)
    • 4.4.1. Wolman Disease (WD) Market, 2018 - 2030 (USD Million)
  • 4.5. Cholesteryl Ester Storage Disease (CESD)
    • 4.5.1. Cholesteryl Ester Storage Disease (CESD) Market, 2018 - 2030 (USD Million)

Chapter 5. Lysosomal Acid Lipase Deficiency Treatment Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Enzyme Replacement Therapy (ERT)
    • 5.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
  • 5.5. Supportive Care
    • 5.5.1. Supportive Care Market, 2018 - 2030 (USD Million)
  • 5.6. Lipid Modifying Agents
    • 5.6.1. Lipid Modifying Agents Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Lysosomal Acid Lipase Deficiency Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lysosomal Acid Lipase Deficiency Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Alexion Pharmaceuticals, Inc. (AstraZeneca)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. BioCrick BioTech
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Lupin
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Merck KGaA
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Pfizer Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Regeneron Pharmaceuticals Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Teva Pharmaceutical Industries Ltd
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
Show more
Product Code: GVR-2-68038-610-3

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lysosomal acid lipase deficiency treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 North America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 Canada lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Mexico lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Europe lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 UK lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Germany lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 France lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 Italy lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Spain lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 28 Norway lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway Lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Denmark lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Sweden lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 37 Japan lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 China lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 India lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 43 Australia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 South Korea lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Thailand lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Latin America lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 52 Brazil lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Argentina lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Lysosomal acid lipase deficiency treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 South Africa lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 UAE lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lysosomal acid lipase deficiency treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lysosomal acid lipase deficiency treatment market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lysosomal acid lipase deficiency treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and treatment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lysosomal acid lipase deficiency treatment market dynamics
  • Fig. 12 Lysosomal acid lipase deficiency treatment market: Porter's five forces analysis
  • Fig. 13 Lysosomal acid lipase deficiency treatment market: PESTLE analysis
  • Fig. 14 Lysosomal acid lipase deficiency treatment market: Indication segment dashboard
  • Fig. 15 Lysosomal acid lipase deficiency treatment market: Indication market share analysis, 2024 & 2030
  • Fig. 16 Wolman disease (WD) market, 2018 - 2030 (USD Million)
  • Fig. 17 Cholesteryl ester storage disease (CESD) market, 2018 - 2030 (USD Million)
  • Fig. 18 Lysosomal acid lipase deficiency treatment market: Treatment segment dashboard
  • Fig. 19 Lysosomal acid lipase deficiency treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 20 Enzyme replacement therapy (ERT) market, 2018 - 2030 (USD Million)
  • Fig. 21 Supportive care market, 2018 - 2030 (USD Million)
  • Fig. 22 Lipid modifying agents market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Lysosomal acid lipase deficiency treatment market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 MEA lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait lysosomal acid lipase deficiency treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!